欧洲-话题@MedSci

#欧洲#

592篇内容 | 6057人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1339383, encodeId=e062133938387, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=欧洲药品管理局（EMA）授予ARU-1801治疗镰状细胞病的优先药品资格（PRIME）, objectType=article, longId=206793, objectId=2ade206e932f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ade206e932f, replyNumber=0, likeNumber=59, createdTime=2021-02-06, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ade206e932f, moduleTitle=欧洲药品管理局（EMA）授予ARU-1801治疗镰状细胞病的优先药品资格（PRIME）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ade206e932f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339382, encodeId=3fed133938243, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=Allergy：加拿大、欧洲、南非和美国过敏性成年人对屋尘螨敏感情况的比较 , objectType=article, longId=206745, objectId=7f19206e4570, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f19206e4570, replyNumber=0, likeNumber=59, createdTime=2021-02-05, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f19206e4570, moduleTitle=Allergy：加拿大、欧洲、南非和美国过敏性成年人对屋尘螨敏感情况的比较 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f19206e4570)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339381, encodeId=e83e1339381a0, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=欧洲监管机构批准阿斯利康-牛津COVID-19疫苗附条件上市, objectType=article, longId=206718, objectId=fb82206e188b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb82206e188b, replyNumber=0, likeNumber=79, createdTime=2021-02-04, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb82206e188b, moduleTitle=欧洲监管机构批准阿斯利康-牛津COVID-19疫苗附条件上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb82206e188b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339380, encodeId=e295133938086, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=欧洲药品管理局接受加速审评传奇生物CAR-T疗法申请, objectType=article, longId=206717, objectId=53f5206e17b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=53f5206e17b0, replyNumber=0, likeNumber=66, createdTime=2021-02-04, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=53f5206e17b0, moduleTitle=欧洲药品管理局接受加速审评传奇生物CAR-T疗法申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=53f5206e17b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339379, encodeId=704f13393e99d, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=欧洲接受CAR-T疗法Ciltacabtagene Autoleucel（Cilta-cel）的加速评估，以治疗多发性骨髓瘤, objectType=article, longId=206689, objectId=8a6220668996, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a6220668996, replyNumber=0, likeNumber=65, createdTime=2021-02-04, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a6220668996, moduleTitle=欧洲接受CAR-T疗法Ciltacabtagene Autoleucel（Cilta-cel）的加速评估，以治疗多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a6220668996)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339378, encodeId=797113393e82f, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=欧洲药品管理局（EMA）开始审查GBT的镰状细胞疗法Oxbryta, objectType=article, longId=206442, objectId=8d542064424c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d542064424c, replyNumber=0, likeNumber=71, createdTime=2021-02-01, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d542064424c, moduleTitle=欧洲药品管理局（EMA）开始审查GBT的镰状细胞疗法Oxbryta, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d542064424c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339377, encodeId=a83513393e7ef, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=欧洲监管机构对Sogroya（somapacitan）治疗成人生长激素缺乏症持积极意见, objectType=article, longId=206440, objectId=319320644031, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=319320644031, replyNumber=0, likeNumber=74, createdTime=2021-02-01, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=319320644031, moduleTitle=欧洲监管机构对Sogroya（somapacitan）治疗成人生长激素缺乏症持积极意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=319320644031)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339376, encodeId=75a913393e648, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=欧洲委员会授予CLR 131治疗Waldenstrom巨球蛋白血症的“孤儿药资格”, objectType=article, longId=206366, objectId=b3d82063663c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3d82063663c, replyNumber=0, likeNumber=74, createdTime=2021-01-30, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3d82063663c, moduleTitle=欧洲委员会授予CLR 131治疗Waldenstrom巨球蛋白血症的“孤儿药资格”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3d82063663c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339375, encodeId=992913393e592, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=2020年欧洲妇科肿瘤学会(ESGO)晚期卵巢癌手术质量指标更新, objectType=article, longId=206085, objectId=4a9920608543, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a9920608543, replyNumber=0, likeNumber=76, createdTime=2021-01-24, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a9920608543, moduleTitle=2020年欧洲妇科肿瘤学会(ESGO)晚期卵巢癌手术质量指标更新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a9920608543)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339374, encodeId=834c13393e452, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=【预防接种日】人乳头瘤病毒（宫颈癌）疫苗接种的立场文件：来自欧洲妇科肿瘤学会- 欧洲阴道镜联盟（ESGO - EFC）, objectType=article, longId=206070, objectId=d7e92060e073, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d7e92060e073, replyNumber=0, likeNumber=55, createdTime=2021-01-24, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d7e92060e073, moduleTitle=【预防接种日】人乳头瘤病毒（宫颈癌）疫苗接种的立场文件：来自欧洲妇科肿瘤学会- 欧洲阴道镜联盟（ESGO - EFC）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d7e92060e073)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339373, encodeId=e00f13393e3e9, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=EUR HEART J-CARD PHA：二氢吡啶对院外心脏骤停的不同影响:来自两个欧洲国家基于人群的真实数据, objectType=article, longId=205308, objectId=ad7c2053085f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad7c2053085f, replyNumber=0, likeNumber=81, createdTime=2021-01-06, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad7c2053085f, moduleTitle=EUR HEART J-CARD PHA：二氢吡啶对院外心脏骤停的不同影响:来自两个欧洲国家基于人群的真实数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad7c2053085f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339372, encodeId=a9c713393e26f, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=欧洲药品管理局批准Zeposia（ozanimod）治疗溃疡性结肠炎, objectType=article, longId=205137, objectId=efdf20513e75, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=efdf20513e75, replyNumber=0, likeNumber=59, createdTime=2021-01-02, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=efdf20513e75, moduleTitle=欧洲药品管理局批准Zeposia（ozanimod）治疗溃疡性结肠炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=efdf20513e75)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339371, encodeId=4aac13393e131, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=BMJ：远在欧洲的足球赛也会影响亚洲的交通事故率吗？, objectType=article, longId=204732, objectId=bb68204e3200, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb68204e3200, replyNumber=0, likeNumber=66, createdTime=2020-12-22, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb68204e3200, moduleTitle=BMJ：远在欧洲的足球赛也会影响亚洲的交通事故率吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb68204e3200)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339370, encodeId=282913393e01c, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=安排！欧洲一些国家发布新冠疫苗接种战略, objectType=article, longId=204142, objectId=bb6c20414290, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb6c20414290, replyNumber=0, likeNumber=57, createdTime=2020-12-06, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb6c20414290, moduleTitle=安排！欧洲一些国家发布新冠疫苗接种战略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb6c20414290)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339369, encodeId=60db133936989, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=3.5亿美元，阿斯利康出售重磅药物Crestor欧洲权益, objectType=article, longId=204104, objectId=cb44204104d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb44204104d5, replyNumber=0, likeNumber=97, createdTime=2020-12-05, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb44204104d5, moduleTitle=3.5亿美元，阿斯利康出售重磅药物Crestor欧洲权益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb44204104d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339368, encodeId=7f921339368ab, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=Bio-Thera向欧洲药品管理局提交了Avastin生物仿制药BAT1706的营销授权申请（MAA）。, objectType=article, longId=203853, objectId=e1e7203853fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1e7203853fc, replyNumber=0, likeNumber=81, createdTime=2020-11-30, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1e7203853fc, moduleTitle=Bio-Thera向欧洲药品管理局提交了Avastin生物仿制药BAT1706的营销授权申请（MAA）。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1e7203853fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339367, encodeId=db65133936eab, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=欧洲委员会批准SYMKEVI联合KALYDECO治疗6-11岁囊性纤维化患儿, objectType=article, longId=203848, objectId=48bb20384867, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48bb20384867, replyNumber=0, likeNumber=94, createdTime=2020-11-30, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48bb20384867, moduleTitle=欧洲委员会批准SYMKEVI联合KALYDECO治疗6-11岁囊性纤维化患儿, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=48bb20384867)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339366, encodeId=ec44133936694, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=欧洲CHMP在11月会议上建议批准5种药物上市, objectType=article, longId=203480, objectId=2f6c203480cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f6c203480cb, replyNumber=0, likeNumber=90, createdTime=2020-11-18, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f6c203480cb, moduleTitle=欧洲CHMP在11月会议上建议批准5种药物上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f6c203480cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339365, encodeId=74df1339365cc, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=Opdivo联合Yervoy：欧洲获批一线治疗转移性非小细胞肺癌, objectType=article, longId=203219, objectId=4e11203219e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e11203219e6, replyNumber=0, likeNumber=70, createdTime=2020-11-11, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e11203219e6, moduleTitle=Opdivo联合Yervoy：欧洲获批一线治疗转移性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e11203219e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339364, encodeId=e5d9133936404, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=阿斯利康的BTK抑制剂Calquence：欧洲获批治疗慢性淋巴细胞白血病, objectType=article, longId=203214, objectId=c984203214b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c984203214b8, replyNumber=0, likeNumber=101, createdTime=2020-11-11, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c984203214b8, moduleTitle=阿斯利康的BTK抑制剂Calquence：欧洲获批治疗慢性淋巴细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c984203214b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

欧洲

2020-05-29

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

欧洲药品管理局（EMA）授予ARU-1801治疗镰状细胞病的优先药品资格（PRIME）

2021-02-06

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

Allergy：加拿大、欧洲、南非和美国过敏性成年人对屋尘螨敏感情况的比较

2021-02-05

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

欧洲监管机构批准阿斯利康-牛津COVID-19疫苗附条件上市

2021-02-04

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

欧洲药品管理局接受加速审评传奇生物CAR-T疗法申请

2021-02-04

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

欧洲接受CAR-T疗法Ciltacabtagene Autoleucel（Cilta-cel）的加速评估，以治疗多发性骨髓瘤

2021-02-04

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

欧洲药品管理局（EMA）开始审查GBT的镰状细胞疗法Oxbryta

2021-02-01

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

欧洲监管机构对Sogroya（somapacitan）治疗成人生长激素缺乏症持积极意见

2021-02-01

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

欧洲委员会授予CLR 131治疗Waldenstrom巨球蛋白血症的“孤儿药资格”

2021-01-30

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

2020年欧洲妇科肿瘤学会(ESGO)晚期卵巢癌手术质量指标更新

2021-01-24

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

【预防接种日】人乳头瘤病毒（宫颈癌）疫苗接种的立场文件：来自欧洲妇科肿瘤学会- 欧洲阴道镜联盟（ESGO - EFC）

2021-01-24

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

EUR HEART J-CARD PHA：二氢吡啶对院外心脏骤停的不同影响:来自两个欧洲国家基于人群的真实数据

2021-01-06

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

欧洲药品管理局批准Zeposia（ozanimod）治疗溃疡性结肠炎

2021-01-02

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

BMJ：远在欧洲的足球赛也会影响亚洲的交通事故率吗？

2020-12-22

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

安排！欧洲一些国家发布新冠疫苗接种战略

2020-12-06

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

3.5亿美元，阿斯利康出售重磅药物Crestor欧洲权益

2020-12-05

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

Bio-Thera向欧洲药品管理局提交了Avastin生物仿制药BAT1706的营销授权申请（MAA）。

2020-11-30

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

欧洲委员会批准SYMKEVI联合KALYDECO治疗6-11岁囊性纤维化患儿

2020-11-30

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

欧洲CHMP在11月会议上建议批准5种药物上市

2020-11-18

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

Opdivo联合Yervoy：欧洲获批一线治疗转移性非小细胞肺癌

2020-11-11

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

阿斯利康的BTK抑制剂Calquence：欧洲获批治疗慢性淋巴细胞白血病

2020-11-11

科室
- - 订阅+
  - 更多科室
工具
服务